HOXA9 and urinary bladder cancer: In urine samples, the methylation status of a urinary biomarker panel (HOXA9, ONECUT2, PCDH17, PENK, TWIST1, VIM, and ZNF154) showed great prediction accuracy in predicting bladder cancer in patients with hematuria [54].